Literature DB >> 22135625

Triple-Negative Breast Cancer: Clinical and Histological Correlations.

Zeinab Elsawaf1, Hans-Peter Sinn.   

Abstract

SUMMARY: Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptors and the lack of HER2 expression or amplification. Much interest has recently been focused on these triple-negative (TN) subtypes because they may be aggressive and are more likely to recur and metastasize than other subtypes of breast cancer. TNBC accounts for approximately 10-24% of all breast cancer cases, and typically it occurs in younger patients and in patients with BRCA1 mutation. There is a substantial heterogeneity of TNBCs both at the morphological and the molecular level, but there are also common features, such as low tumor grade and accelerated tumor proliferation. Morphologically, TNBC may present as invasive ductal, metaplastic, medullary, apocrine, or other types. Molecularly, they are most frequently associated with a basal phenotype, but there is a distinct subgroup of cancers that are not of basal type and belong to the claudin-low or molecular-apocrine type. The basal phenotype is frequently associated with the loss of BRCA1.

Entities:  

Year:  2011        PMID: 22135625      PMCID: PMC3225211          DOI: 10.1159/000331643

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  85 in total

1.  Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).

Authors:  Emad A Rakha; Ian O Ellis; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2008-08       Impact factor: 7.842

2.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

3.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

4.  p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.

Authors:  T Crook; L A Brooks; S Crossland; P Osin; K T Barker; J Waller; E Philp; P D Smith; I Yulug; J Peto; G Parker; M J Allday; M R Crompton; B A Gusterson
Journal:  Oncogene       Date:  1998-10-01       Impact factor: 9.867

Review 5.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

Review 6.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

7.  Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.

Authors:  Gamze Gokoz Dogu; Metin Ozkan; Figen Ozturk; Mustafa Dikilitas; Ozlem Er; Ahmet Ozturk
Journal:  Med Oncol       Date:  2009-01-21       Impact factor: 3.064

8.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Authors:  S R Young; Robert T Pilarski; Talia Donenberg; Charles Shapiro; Lyn S Hammond; Judith Miller; Karen A Brooks; Stephanie Cohen; Beverly Tenenholz; Damini Desai; Inuk Zandvakili; Robert Royer; Song Li; Steven A Narod
Journal:  BMC Cancer       Date:  2009-03-19       Impact factor: 4.430

9.  Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.

Authors:  Zhe-Bin Liu; Jiong Wu; Bo Ping; Li-Qing Feng; Gen-Hong Di; Jin-Song Lu; Kun-Wei Shen; Zhen-Zhou Shen; Zhi-Min Shaol
Journal:  Tumori       Date:  2009 Jan-Feb

10.  Early onset of breast cancer in a group of British black women.

Authors:  R L Bowen; S W Duffy; D A Ryan; I R Hart; J L Jones
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

View more
  15 in total

1.  New Clues to Breast Cancer Heterogeneity.

Authors:  Kreipe Hans
Journal:  Breast Care (Basel)       Date:  2011-08-29       Impact factor: 2.860

Review 2.  To differentiate or not--routes towards metastasis.

Authors:  Thomas Brabletz
Journal:  Nat Rev Cancer       Date:  2012-05-11       Impact factor: 60.716

3.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.

Authors:  Ji Hyun Youk; Eun Ju Son; Jin Chung; Jeong-Ah Kim; Eun-Kyung Kim
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

4.  PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients.

Authors:  Rudolf Napieralski; Gabriele Schricker; Gert Auer; Michaela Aubele; Jonathan Perkins; Viktor Magdolen; Kurt Ulm; Moritz Hamann; Axel Walch; Wilko Weichert; Marion Kiechle; Olaf G Wilhelm
Journal:  Breast Care (Basel)       Date:  2020-12-17       Impact factor: 2.268

5.  Effect of miR-133b on progression and cisplatin resistance of triple-negative breast cancer through FGFR1-Wnt-β-catenin axis.

Authors:  Yan Lin; Fengkang Lin; Songyot Anuchapreeda; Rujirek Chaiwongsa; Suwit Duangmano; Bing Ran; Sakorn Pornprasert
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

6.  Timeline metastatic progression: in the wake of the « seed and soil » theory.

Authors:  Aymeric Amelot; Louis-Marie Terrier; Jean-Jacques Mazeron; Charles-Ambroise Valery; Philippe Cornu; Alexandre Carpentier; Marc Leveque
Journal:  Med Oncol       Date:  2017-10-06       Impact factor: 3.064

7.  HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.

Authors:  Wen-Yee Chay; Sung-Hock Chew; Whee-Sze Ong; Inny Busmanis; Xinyun Li; Sharyl Thung; Lynette Ngo; Sheow-Lei Lim; Yong-Kuei Lim; Yin-Nin Chia; Elisa Koh; Cindy Pang; Lay-Tin Soh; Jin Wang; Tew-Hong Ho; Sun-Kuie Tay; Soo-Kim Lim-Tan; Kiat-Hon Lim; John Whay-Kuang Chia; Liang-Kee Goh
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

8.  β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.

Authors:  Jinhua Xu; Jenifer R Prosperi; Noura Choudhury; Olufunmilayo I Olopade; Kathleen H Goss
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 9.  Triple negative breast cancer: the kiss of death.

Authors:  Adriana-Andreea Jitariu; Anca Maria Cîmpean; Domenico Ribatti; Marius Raica
Journal:  Oncotarget       Date:  2017-07-11

10.  A clinical study on the use of Huaier granules in post-surgical treatment of triple-negative breast cancer.

Authors:  Minghao Wang; Ying Hu; Lingmi Hou; Qinwen Pan; Peng Tang; Jun Jiang
Journal:  Gland Surg       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.